At the American Diabetes Association’s 2026 Scientific Sessions, Dexcom presented impactful results from the CONNECT randomized controlled trial. In this study, the Dexcom G7 continuous glucose monitor (CGM) generated clinically significant improvements in glucose control for people with type 2 diabetes who are not using insulin.

Researchers analyzed 265 participants over the course of a 26-week study. Participants using Dexcom G7 saw an average A1C reduction of 1.6% from a baseline of 8.8%. The control group using standard blood glucose monitoring only saw a 0.9% reduction. Those with initial A1C levels above 10% saw even more significant A1C reductions—3.1% on average. Study participants using the G7 also spent about five more hours per day within the healthy glucose target range compared to the control group. The device showed an additive benefit when combined with diabetes medications like GLP-1s and SGLT2s.

The study is notable for providing the first "Level A" evidence, the highest evidence grade recognized by the ADA, which historically has driven changes in standards of care. The company hopes this leads to expanded Medicare coverage and additional insurance benefits for Dexcom G7 users. We would love to hear from our type 2 community. Do you use a CGM? Is it helpful in your day-to-day management? Let us know in the comments!

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a healthcare team before making changes to your treatment.